Tuesday March 20, 2018

Viral hepatitis Caused 1.34 mn Deaths Globally: Study

Viral hepatitis was found to be amongst the top ten leading global killers

Viral hepatitis
World Health Organization poster for Hepatitis Campaign. VOA

London, Sep 16, 2017: Viral hepatitis with 1.34 million deaths globally has surpassed all chronic infectious diseases including HIV/AIDS, malaria and tuberculosis, according to a study by Global Burden of Disease.

The study reveals that in 2016, the total deaths caused by viral hepatitis, including liver cancer, acute cases, cirrhosis, hepatitis A, E, B, C and D account for 1.34 million globally, exceeding tuberculosis (1.2 million), HIV/AIDS (1 million) and malaria (719,000).

These staggering death rates occurred despite recent advances in hepatitis C medications that can cure most infections within three months and the availability of highly-effective vaccinations for hepatitis B.

“It’s outrageous, but not surprising, that the Global Burden of Disease Report found that deaths related to viral hepatitis have surpassed HIV, TB and malaria” said Charles Gore, President of the World Hepatitis Alliance — a not-for profit organisation based in London.

“This is largely due to a historic lack of political prioritisation coupled with an absent global funding mechanism,” Gore added, in the paper published in the journal the Lancet.

Further, viral hepatitis was found to be amongst the top ten leading global killers which include heart disease, road accidents, Alzheimer’s disease, amongst others.

Also Read: WHO Calls for stepped up action to Eliminate Hepatitis B and C by 2030 

If this trend has to be reversed, immediate action must be taken at both a regional and national level, said the report, while suggesting measures such as scaling up testing and diagnosis.

Viral hepatitis is a highly contagious liver infection caused by the hepatitis A virus and only 5 per cent of people living with the disease are aware of their conditions there are only few noticeable symptoms.

As a result, many people are either misdiagnosed or do not come forward for testing, increasing the chance of infecting others and missing the opportunity to access life-saving treatment.

Reducing hepatitis related deaths by 65 per cent by 2030 is a key component of the World Health Organization’s Global Hepatitis Strategy.

The strategy, which was adopted by 194 governments, sets out a list of key targets, which, if achieved, will eliminate viral hepatitis by 2030. (IANS)


Click here for reuse options!
Copyright 2017 NewsGram

Next Story

Pentavalent vaccine: Doctors raise red flag

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive

the new Hepatitis B vaccine for adults is called Heplisav-B.
India's PV to be reexamined because of its harmful effects. .
  • Pentavalent vaccine was introduced in India six years ago
  • It is since then have been a cause of many deaths
  • Doctors want it to be reexamined before continuing its use

Pentavalent vaccine (PV), that was introduced by India a little over six years ago, doubled the deaths of children soon after vaccination compared to the DPT (Diphtheria-Pertussis-Tetanus) vaccine, according to a new study that calls for a “rigorous review of the deaths following vaccination with PV”.

Health officials have launched a campaign targeting nearly 24 million people with a one-fifth dose of the vaccine. Wikimedia Commons
PV has been cause of many deaths in past years. Wikimedia Commons

Government records show that there were 10,612 deaths following vaccination (both PV and DPT) in the last 10 years. There was a huge increase in these numbers in 2017, which the Health Ministry has promised to study. “The present analysis could be a starting point in the quest to reduce the numbers of such deaths,” authors of the new study say.

The study by Dr Jacob Puliyel, Head of Pediatrics at St Stephens Hospital, and Dr V. Sreenivas, Professor of Biostatistics at the All-India Institute of Medical Sciences (AIIMS), both in New Delhi, is published in the peer-reviewed Medical Journal of Dr D.Y. Patil University.

PV is a combination of the DPT vaccine and two more vaccines against Haemophilus influenza type B (Hib) and hepatitis B. Starting December 2011, PV was introduced into India’s immunisation programme to replace DPT vaccine in a staged manner with a view to adding protection against Hib and Hepatitis B without increasing the number of injections given to infants.

Doctors have raised concerns over these vaccines. Wikimedia Commons
Doctors have raised concerns over these vaccines. Wikimedia Commons

But sporadic reports of unexplained deaths following immunisation with PV had been a matter of concern. Puliyel, Sreenivas and their colleagues undertook the study to find out if these deaths were merely coincidental or vaccine-induced.

The authors obtained data of all deaths reported from April 2012 to May 2016 under the Right to Information Act. Data on deaths within 72 hours of administering DPT and PV from different states were used.

For their study, the authors assumed that all deaths within 72 hours of receiving DPT are natural deaths. Using this figure as the baseline, they presumed that any increase in the number of deaths above this baseline among children receiving PV must be caused by this vaccine.

Also Read: With Medicine Running Out, Venezuelans With Transplant Live in Fear

According to their analysis of the data provided by the government, there were 237 deaths within 72 hours of administering the Pentavalent vaccine — twice the death rate among infants who received DPT vaccine.

Extrapolating the data, the authors have estimated that vaccination of 26 million children each year in India would result in 122 additional deaths within 72 hours, due to the switch from DPT to PV.

“There is likely to be 7,020 to 8,190 deaths from PV each year if data from states with the better reporting, namely Manipur and Chandigarh, are projected nationwide,” their report says.

It is important to make sure that these vaccines are reexamined peroperly. VOA

The authors note that while the study looks at the short-term increase in deaths (within three days of vaccination) it does not calculate the potential benefits of PV on infant mortality, for example by protection against lethal diseases like Haemophilus influenza.

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive. “These findings of differential death rates between DPT and PV do call for further rigorous prospective population-based investigations,” the study concludes. IANS